A Randomized, Open-Label Pilot Trial to Evaluate the Safety and Efficacy of Carmustine Wafer in Combination with Retifanlimab and Standard Radiation With or Without Temozolomide in Newly-Diagnosed Adult Subjects with Glioblastoma

Disease Sites:

Neuro-Oncology, Phase I

Staging:

Phase I

Age Group:

Adults

Therapies:

Mol. targeted/Immunotherapy/Biologics, Radiotherapy

Drugs:

Not Available

Principal Investigator(s):

Thompson, Reid

Scope:

National

Participating Institutions:

Vanderbilt University

Open Date:

12-08-2023

Trial Type:

Treatment

Protocol ID:

VICCNEUP22119

National Clinical Trial ID:

NCT05083754

Eligibility

Ages Eligible for Study:

Not Available

Genders Eligible for Study:

Not Available

Accepts Healthy Volunteers?:

Not Available